Murielle Gantzer

1.1k total citations · 1 hit paper
13 papers, 915 citations indexed

About

Murielle Gantzer is a scholar working on Genetics, Molecular Biology and Oncology. According to data from OpenAlex, Murielle Gantzer has authored 13 papers receiving a total of 915 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Genetics, 5 papers in Molecular Biology and 4 papers in Oncology. Recurrent topics in Murielle Gantzer's work include Virus-based gene therapy research (11 papers), Cancer Research and Treatments (4 papers) and CAR-T cell therapy research (3 papers). Murielle Gantzer is often cited by papers focused on Virus-based gene therapy research (11 papers), Cancer Research and Treatments (4 papers) and CAR-T cell therapy research (3 papers). Murielle Gantzer collaborates with scholars based in France and Germany. Murielle Gantzer's co-authors include A Dieterlé, Eric Degryse, Cécile Chartier, Andréa Pavirani, Majid Mehtali, Éric Quéméneur, Xavier Préville, Laetitia Fend, Laurence Zitvogel and Karola Rittner and has published in prestigious journals such as Cancer Research, Journal of Virology and Scientific Reports.

In The Last Decade

Murielle Gantzer

13 papers receiving 890 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Efficient generation of recombinant adenovirus vectors by homologous recombination in Escherichia coli

1996 591 citations Cécile Chartier, Eric Degryse et al. Journal of Virology profile →

Peers

Countries citing papers authored by Murielle Gantzer

Since Specialization

Citations

This map shows the geographic impact of Murielle Gantzer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Murielle Gantzer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Murielle Gantzer more than expected).

Fields of papers citing papers by Murielle Gantzer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Murielle Gantzer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Murielle Gantzer. The network helps show where Murielle Gantzer may publish in the future.

Co-authorship network of co-authors of Murielle Gantzer

This figure shows the co-authorship network connecting the top 25 collaborators of Murielle Gantzer. A scholar is included among the top collaborators of Murielle Gantzer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Murielle Gantzer. Murielle Gantzer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

13 of 13 papers shown

#	Work	Indexed citations
1	Oncolytic virotherapy with intratumoral injection of vaccinia virus TG6002 and 5-fluorocytosine administration in dogs with malignant tumors 2023 ·Molecular Therapy — Oncolytics ·(unknown), Eve Laloy, (unknown), Murielle Gantzer, (unknown), (unknown), (unknown), Johann Foloppe, Jean‐Marc Balloul, Christelle Machon, Jérôme Guitton, Dominique Tierny, Bernard Klonjkowski, Éric Quéméneur, Christelle Maurey, Philippe Erbs	6
2	Safety, biodistribution and viral shedding of oncolytic vaccinia virus TG6002 administered intravenously in healthy beagle dogs 2021 ·Scientific Reports ·(unknown), Murielle Gantzer, (unknown), Johann Foloppe, Bernard Klonjkowski, Christelle Maurey, Éric Quéméneur, Philippe Erbs	7
3	Safety studies and viral shedding of intramuscular administration of oncolytic vaccinia virus TG6002 in healthy beagle dogs 2020 ·BMC Veterinary Research ·(unknown), (unknown), Murielle Gantzer, (unknown), Johann Foloppe, Jean‐Marc Balloul, Eve Laloy, Dominique Tierny, Bernard Klonjkowski, Éric Quéméneur, Christelle Maurey, Philippe Erbs	6
4	Abstract 1446: Characterization, evaluation and safety studies of the oncolytic Vaccinia virus TG6002 for canine cancer therapy 2019 ·Cancer Research ·(unknown), Johann Foloppe, Eve Laloy, (unknown), (unknown), Murielle Gantzer, (unknown), (unknown), Pascale Cordier, Dominique Tierny, (unknown), Éric Quéméneur, Christelle Maurey, Bernard Klonjkowski, Philippe Erbs	2
5	Immune Checkpoint Blockade, Immunogenic Chemotherapy or IFN-α Blockade Boost the Local and Abscopal Effects of Oncolytic Virotherapy 2017 ·Cancer Research ·Laetitia Fend, Takahiro Yamazaki, (unknown), (unknown), Murielle Gantzer, (unknown), Xavier Préville, Éric Quéméneur, Oliver Kepp, Julien Adam, Aurélien Marabelle, Jonathan M. Pitt, Guido Kroemer, Laurence Zitvogel	108
6	Viral based vaccine TG4010 induces broadening of specific immune response and improves outcome in advanced NSCLC 2017 ·Journal for ImmunoTherapy of Cancer ·(unknown), Bérangère Bastien, Luc Barraud, (unknown), (unknown), Murielle Gantzer, J.M. Limacher, Éric Quéméneur, Kaïdre Bendjama, Xavier Préville	47
7	Sequential administration of MVA-based vaccines and PD-1/PD-L1-blocking antibodies confers measurable benefits on tumor growth and survival: Preclinical studies with MVA-βGal and MVA-MUC1 (TG4010) in a murine tumor model 2017 ·Human Vaccines & Immunotherapeutics ·(unknown), Christine Thioudellet, (unknown), Murielle Gantzer, (unknown), (unknown), (unknown), Xavier Préville, Kaïdre Bendjama, Éric Quéméneur, Karola Rittner	27
8	Vectorization in an oncolytic vaccinia virus of an antibody, a Fab and a scFv against programmed cell death -1 (PD-1) allows their intratumoral delivery and an improved tumor-growth inhibition 2016 ·OncoImmunology ·(unknown), Laetitia Fend, Christine Thioudellet, Michel Geist, (unknown), (unknown), (unknown), D Schmitt, Murielle Gantzer, (unknown), (unknown), Dominique Villeval, Karola Rittner, Nathalie Silvestre, Philippe Erbs, Laurence Zitvogel, Éric Quéméneur, Xavier Préville, Jean‐Baptiste Marchand	84
9	Abstract 2497: Immune checkpoint inhibitors enhance benefits of modified vaccinia virus Ankara to improve survival in preclinical models of cancer 2015 ·Cancer Research ·Karola Rittner, (unknown), (unknown), (unknown), (unknown), (unknown), Murielle Gantzer, Christine Thioudellet, Philippe Slos, Xavier Préville	1
10	Intravenous Injection of MVA Virus Targets CD8+ Lymphocytes to Tumors to Control Tumor Growth upon Combinatorial Treatment with a TLR9 Agonist 2014 ·Cancer Immunology Research ·Laetitia Fend, (unknown), Jacqueline Kintz, Murielle Gantzer, (unknown), Karola Rittner, (unknown), Sylvie Fournel, Xavier Préville	17
11	Fusokine Interleukin-2/Interleukin-18, a Novel Potent Innate and Adaptive Immune Stimulator with Decreased Toxicity 2005 ·Cancer Research ·Bruce Acres, Murielle Gantzer, (unknown), (unknown), Nathalie Accart, Olivier Chaloin, Johan Hoebeke, Jean‐Marc Balloul, Stéphane Paul	10
12	Constitutive Expression of the Adenovirus E3-14.7K Protein Does Not Prolong Adenovirus Vector DNA Persistence but Protects Mice Against Lipopolysaccharide-Induced Acute Hepatitis 2002 ·Human Gene Therapy ·Murielle Gantzer, (unknown), (unknown), Ronald Rooke	9
13	Efficient generation of recombinant adenovirus vectors by homologous recombination in Escherichia coli breakdown → 1996 ·Journal of Virology ·Cécile Chartier, Eric Degryse, Murielle Gantzer, A Dieterlé, Andréa Pavirani, Majid Mehtali	591

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact